Rejuvenate Bio

Rejuvenate Bio is a private, pre-clinical stage biotech pioneering a novel approach to treating aging as a root cause of chronic disease. Its core technology involves using adeno-associated virus (AAV) vectors to deliver longevity-associated genes, such as FGF21, into the liver, creating a durable source of therapeutic protein secretion to address multiple age-related conditions simultaneously. The company has adopted a dual-path strategy, pursuing an early revenue opportunity in veterinary medicine through a partnership for canine mitral valve disease while advancing its foundational human therapeutics. This approach is designed to de-risk and fund the longer-term development of transformative gene therapies for human age-related diseases.

Liver-directed AAV gene therapy platform for durable expression of secreted therapeutic proteins (e.g., FGF21) to systemically treat multiple age-related conditions.

Rejuvenate Bio operates in the competitive longevity biotech space, alongside companies like Unity Biotechnology, Calico, and Life Biosciences, all targeting aging mechanisms. Its specific focus on systemic, protein-secreting gene therapy differentiates it from many senolytic or small-molecule approaches. In veterinary gene therapy, it faces competition from companies like Lysogen and others developing advanced therapies for pets.